56355-15-8

Upstream product

• 938-96-5 2-(4-Hydroxy-phenyl)-propionic acid 
• 64-17-5 ethanol 

Downstream Products

• 80772-66-3 2-[4-(2-Cyano-cyclohexylmethoxy)-phenyl]-propionic acid ethyl ester 
• 55922-76-4 4-(2-carboxybenzyloxy)-α-methylphenylacetic acid 
• 73621-47-3 ethyl 4-benzyloxyphenylpropionate 
• 56355-16-9 ethyl 2-[4-(2-thiazolyloxy)-phenyl]propionate 
• 59346-80-4 ethyl 2-(3-nitro-4-hydroxyphenyl)propionate 

Relevant academic research and scientific papers

Lipase-catalyzed hydrolysis of 2-(4-hydroxyphenyl)propionic acid ethyl ester to (R)-(?)-2-(4-hydroxyphenyl)propanoic acid

Stereoselective hydrolysis of (±)-2-(4-hydroxyphenyl)propionic acid ethyl ester (2-HPPAEE) by lipase catalyzed in aqueous system was investigated. Lipase AK with higher catalytic activity and enantioselectivity was selected as catalyst. Simultaneously, factors affecting the conversion of substrate (c) and the enantiomeric excess of product (eep) were optimized. The optimal conditions were established, involving 45?°C of temperature, 5.5 of pH, 10?mg of lipase AK dosage, 0.04?mmol of substrate dosage and 40?h of reaction time. Under the optimum conditions, c and eep could reach up to 49% and 98%, respectively.

Pyrrolidine derivatives, pharmaceutical compositions and uses thereof

Pyrrolidine derivatives which are inhibitors of acetyl-CoA carboxylase(s) and their use in the treatment of obesity and type-2 diabetes. An exemplary compound is 2-(4-(1-[5-Chloro-6-(2-hydroxy-2-methyl-propoxy)-pyrimidin-4-yl]-(R)-pyrrolidin-3-yloxy)-phen

PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

The invention relates to new pyrrolidine derivatives of the formula (I), wherein R1 to R5, Ar1, Ar2 and n are as defined in the description and claims, to their use as medicaments, to methods for their therapeut

Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process for Making Them, and Use Thereof for Treating Pain and Other Conditions

Vanilloid receptor ligand compounds corresponding to formula I: pharmaceutical compositions containing such compounds, a process for producing such compounds, and methods of using such compounds for treating or inhibiting pain and various other disorders or conditions.

4-substituted piperidine analogs and their use as subtype selective NMDA receptor antagonists

PCT No. PCT/US96/20872 Sec. 371 Date Sep. 16, 1998 Sec. 102(e) Date Sep. 16, 1998 PCT Filed Dec. 20, 1996 PCT Pub. No. WO97/23216 PCT Pub. Date Jul. 3, 1997Novel 4-substituted piperidine analogs, pharmaceutical compositions containing the same and the method of using 4-substituted piperidine analogs are selective active antagonists of N-methyl-D-aspartate (NMDA) receptor subtypes for treating conditions such as stroke, cerebral ischemia, central nervous system trauma, hypoglycemia, psychosis, anxiety, migraine headaches, glaucoma, CMV retinitis, aminoglycoside antibiotics-induced hearing loss, convulsions, chronic pain, opioid tolerance or withdrawal, urinary incontinence or neurodegenerative disorders, such as lathyrism, Alzheimer's Disease, Parkinsonism and Huntington's Disease are described.